High-dose trivalent inactivated influenza vaccine

BIOLOGICAL4 trials

Sponsors

Vanderbilt University, Sanofi Pasteur, a Sanofi Company

Conditions

InfluenzaPediatric Patients With Acute Lymphoblastic LeukemiaPediatric Solid Organ Transplant Patients

Phase 1

Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients

CompletedNCT01216332

Vanderbilt UniversityPediatric Patients With Acute Lymphoblastic Leukemia

Start: 2010-10-31End: 2013-05-31Updated: 2019-05-03

Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients

CompletedNCT01525004

Vanderbilt UniversityPediatric Solid Organ Transplant Patients

Start: 2011-09-30End: 2012-12-31Updated: 2016-08-16

Phase 2

A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age

CompletedNCT01258595

Sanofi Pasteur, a Sanofi CompanyInfluenza

Start: 2010-11-30End: 2011-04-30Updated: 2016-05-16

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

CompletedNCT02553343

Sanofi Pasteur, a Sanofi CompanyInfluenza

Start: 2015-09-30End: 2016-04-04Updated: 2018-02-09